Sugi Predict

Sugi Predict / Compounds / SCHEMBL2840464

SCHEMBL2840464

SCHEMBL2840464

CC(C)(C)OC(=O)N1[C@@H](c2cccc(OCc3ccccc3)c2)CC[C@H]1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 4/20 0.46
▸ KCNH2 Q12809 1/20 0.45
▸ YAP1 P46937 2/20 0.43
▸ GHSR Q92847 4/20 0.42
▸ MAOB P27338 1/20 0.42
▸ SPHK1 Q9NYA1 1/20 0.42
▸ PRMT5 O14744 1/20 0.41
▸ GRIN1 Q05586 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12973314 0.92 KCNH2 (0.51) KCNH2YAP1GHSRMAOBSPHK1
SCHEMBL1104550 0.91 YAP1 (0.46) KCNH2YAP1GHSR
SCHEMBL311160 0.89 FFAR2 (0.49) FFAR2KCNH2YAP1PRMT5
SCHEMBL840904 0.89 FFAR2 (0.49) FFAR2KCNH2YAP1PRMT5
SCHEMBL841242 0.89 FFAR2 (0.49) FFAR2KCNH2YAP1PRMT5
SCHEMBL2832488 0.86 FFAR2 (0.52) FFAR2KCNH2MAOBSPHK1
SCHEMBL2896922 0.82 FFAR2 (0.51) FFAR2
SCHEMBL475745 0.82 FFAR2 (0.51) FFAR2
SCHEMBL859599 0.82 FFAR2 (0.51) FFAR2
SCHEMBL6183606 0.82 FFAR2 (0.51) FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855218-B2 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels Convergence Pharmaceuticals Limited (GB) 2010-12-21 — — US disclosed
US-7855218-B2 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels Convergence Pharmaceuticals Limited (GB) 2010-12-21 — — US disclosed
US-7855218-B2 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels Convergence Pharmaceuticals Limited (GB) 2010-12-21 — — US disclosed
EP-1943216-B1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LTD (GB) 2010-06-30 — — EP disclosed
EP-1943216-B1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LTD (GB) 2010-06-30 — — EP disclosed
US-20080306122-A1 Novel Compounds Convergence Pharmaceuticals Limited (GB) 2008-12-11 — — US disclosed
US-20080306122-A1 Novel Compounds Convergence Pharmaceuticals Limited (GB) 2008-12-11 — — US disclosed
US-20080306122-A1 Novel Compounds Convergence Pharmaceuticals Limited (GB) 2008-12-11 — — US disclosed
WO-2007042250-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306122-A1 Novel Compounds CYP11B1, CYP11B2, CYP46A1 FFAR2 1225/4885KCNH2 3313/4885YAP1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.